SHANGHAI, April 27, 2011 /PRNewswire-Asia/ --WuXi PharmaTech (Cayman) Inc. (NYSE: WX) today announced that it filed its annual report on Form 20-F for the year ended December 31, 2010 with the Securities and Exchange Commission. The annual report can be accessed on WuXi PharmaTech's website at http://www.wuxiapptec.com under the Investor Relations section. WuXi PharmaTech will provide a hard copy of its annual report on Form 20-F containing complete audited financial statements free of charge to its shareholders and ADS holders upon request. Requests should be directed to Ronald Aldridge, Director of Investor Relations, by email at [email protected].
(Logo: http://www.newscom.com/cgi-bin/prnh/20040705/CNM002LOGO)
About WuXi PharmaTech
WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com .
|
For more information, please contact: |
|
|
WuXi PharmaTech (Cayman) Inc. |
|
|
Ronald Aldridge (for investors) |
|
|
Director of Investor Relations |
|
|
Tel: +1-201-585-2048 |
|
|
Email: [email protected] |
|
|
Stephanie Liu (for the media) |
|
|
Tel: +86-21-5046-4362 |
|
|
Email: [email protected] |
|
SOURCE WuXi PharmaTech (Cayman) Inc